Myocardial toxic effects during recombinant interleukin-2 therapy

Area of Science:

• Oncology
• Cardiology
• Immunotherapy

Background:

• Recombinant interleukin-2 (rIL-2) is an immunotherapy used for metastatic solid tumors.
• Cardiopulmonary side effects are known, but cardiac-specific toxicity requires further investigation.

Purpose of the Study:

• To monitor the cardiopulmonary effects of rIL-2 in patients with metastatic solid tumors.
• To investigate the incidence and potential causes of myocardial infarction (MI) during rIL-2 therapy.

Main Methods:

• Ten patients with metastatic solid tumors received iv rIL-2 (100,000 U/kg every 8 hours, days 1-5).
• Cardiopulmonary effects were monitored using arterial and pulmonary artery catheters.
• Electrocardiogram (ECG) and creatinine phosphokinase myocardial band (CK-MB) fractions were used to assess cardiac injury.

Main Results:

• All patients developed severe capillary leak syndrome.
• Three patients experienced myocardial infarction (MI), indicated by ECG changes and elevated CK-MB.
• A significant reduction in left ventricular stroke work index (cardiac contractility) was observed in all patients.

Conclusions:

• rIL-2 therapy can lead to severe capillary leak syndrome and myocardial infarction in cancer patients.
• The exact mechanism of rIL-2-induced MI remains unclear, possibly related to capillary leak syndrome or direct cardiac effects.